Form 8-K - Current report:
SEC Accession No. 0001493152-24-051125
Filing Date
2024-12-20
Accepted
2024-12-20 17:30:05
Documents
19
Period of Report
2024-12-16
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 49786
2 ex4-1.htm EX-4.1 67531
3 ex4-2.htm EX-4.2 99286
4 ex10-1.htm EX-10.1 77998
5 ex10-2.htm EX-10.2 78045
6 ex10-2_01.jpg GRAPHIC 3162
7 image_001.jpg GRAPHIC 2294
  Complete submission text file 0001493152-24-051125.txt   624134

Data Files

Seq Description Document Type Size
8 XBRL SCHEMA FILE ppcb-20241216.xsd EX-101.SCH 3012
9 XBRL LABEL FILE ppcb-20241216_lab.xml EX-101.LAB 34240
10 XBRL PRESENTATION FILE ppcb-20241216_pre.xml EX-101.PRE 24163
21 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3335
Mailing Address 302/6 BUTLER STREET CAMBERWELL, VICTORIA C3 3124
Business Address 302/6 BUTLER STREET CAMBERWELL, VICTORIA C3 3124 61-03-9882-0780
Propanc Biopharma, Inc. (Filer) CIK: 0001517681 (see all company filings)

EIN.: 330662986 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 8-K | Act: 34 | File No.: 000-54878 | Film No.: 241569079
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)